News | Alzheimer's Prevention Registry

You are here

News

Come back regularly for the latest news and information about Alzheimer’s disease and prevention.

May 1, 2020
by Scientific American
It is time to start anew. More than a century after neuropathologist Alois Alzheimer gave the first scientific talk describing the disease that bears his name today, we have no good treatments for...
In the late 1890s, a railroad worker in Frankfurt Germany noticed that his wife, Auguste Deter, was behaving oddly. Gradually her anxiety and mood changes gave way to memory loss, delusions and other...
The Alzheimer’s gene, known as ApoE4, is one of the the largest genetic risk factors for later onset Alzheimer’s disease. Carrying one copy of the gene triples the risk of...
April 16, 2020
by National Institute on Aging
Findings in two separate NIA-funded papers focus on different ways to develop noninvasive, less expensive ways to detect very early-stage Alzheimer’s disease in cognitively healthy people. The...
In the largest study to date of proteins related to Alzheimer’s disease, a team of researchers has identified disease-specific proteins and biological processes that could be developed into both new...
March 18, 2020
by Alzheimer's Prevention Bulletin
Who is watching out for your safety in a clinical trial?  Learn how independent data safety monitoring boards are used to evaluate the safety of the trial and make sure participants are...
January 22, 2020
by Alzheimer's Prevention Bulletin
A woman in Colombia was destined to develop Alzheimer’s disease in her 40’s because of a rare family genetic mutation. But she didn’t show symptoms until her 70’s. Scientists are now investigating...
When biotechnology company Biogen announced the cancellation of the trial for their Alzheimer’s drug aducanumab, nearly 3,500 trial participants were left in limbo. Now, following the...
December 6, 2019
by Scientific American
Pharmaceutical giant Biogen now admits that it made a mistake back in March when it stopped a pair of trials of an experimental Alzheimer’s drug. A deep analysis of the data, released Thursday,...
If regulators approve it, the drug could become the first new medicine for Alzheimer's patients in nearly two decades.